Comparison of Dapagliflozin (DAPA) and Once-weekly Exenatide (EQW), Co-administered or Alone, DAPA/ Glucophage (DAPA/MET ER) and Phentermine/Topiramate (PHEN/TPM) ER on Metabolic Profiles and Body Composition in Obese PCOS Women

Next Previous
Trial Profile

Comparison of Dapagliflozin (DAPA) and Once-weekly Exenatide (EQW), Co-administered or Alone, DAPA/ Glucophage (DAPA/MET ER) and Phentermine/Topiramate (PHEN/TPM) ER on Metabolic Profiles and Body Composition in Obese PCOS Women

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Mar 2018

At a glance

  • Drugs Dapagliflozin (Primary) ; Dapagliflozin/metformin (Primary) ; Exenatide (Primary) ; Phentermine/topiramate
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Pharmacodynamics

    • Most Recent Events

    • 21 Mar 2018 Planned primary completion date changed from 1 Jan 2019 to 1 Feb 2019.
    • 10 Jun 2017 Biomarkers information updated
    • 08 May 2017 Planned End Date changed from 1 Sep 2018 to 1 Apr 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top